| Valuation method | Value, ¥ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 1169.03 | -9 |
| Intrinsic value (DCF) | 1150.64 | -11 |
| Graham-Dodd Method | 1737.83 | 35 |
| Graham Formula | 2633.00 | 104 |
Kohjin Bio Co., Ltd. is a Japan-based biotechnology company specializing in the production and sale of animal blood, sera, tissue culture media, and in-vitro diagnostic agents. Operating in the healthcare sector, Kohjin Bio serves research, clinical, and industrial applications with a diverse product portfolio that includes tissue culture mediums for virus production, hybridoma, and human lymphocyte culture, as well as clinical microbiology culture mediums. The company also provides normal human blood, serum, and plasma, along with preserved animal blood and custom-designed products. With a strong presence in Japan, Kohjin Bio supports advancements in biotechnology, pharmaceuticals, and diagnostics through high-quality biological materials. The company, headquartered in Sakado, Japan, has a market capitalization of approximately ¥8.23 billion (as of latest data) and continues to innovate in cell culture and microbiology solutions. Kohjin Bio’s expertise in specialized media and reagents positions it as a key player in the life sciences supply chain.
Kohjin Bio Co., Ltd. presents a niche investment opportunity in the biotechnology sector, with a focus on high-demand biological materials for research and diagnostics. The company reported revenue of ¥4.77 billion and net income of ¥384 million for FY 2024, with a diluted EPS of ¥92.2. Its operating cash flow of ¥823.68 million and cash reserves of ¥1.73 billion suggest reasonable liquidity, though total debt stands at ¥2.47 billion. The company’s negative beta (-0.37) indicates low correlation with broader market movements, potentially offering defensive characteristics. However, investors should consider the competitive nature of the biotech industry and Kohjin Bio’s reliance on specialized markets. The dividend yield, with a payout of ¥49 per share, may appeal to income-focused investors, but growth prospects depend on continued demand for cell culture and diagnostic products.
Kohjin Bio Co., Ltd. operates in a specialized segment of the biotechnology industry, focusing on animal blood derivatives, tissue culture media, and diagnostic reagents. Its competitive advantage lies in its diversified product portfolio catering to research, clinical, and industrial applications. The company’s expertise in cell culture media and microbiology testing positions it as a reliable supplier for pharmaceutical and diagnostic companies. However, Kohjin Bio faces competition from larger global players with broader R&D capabilities and distribution networks. Its Japan-centric operations may limit international growth compared to multinational competitors. The company’s ability to provide custom-designed biological products offers differentiation, but pricing pressure and technological advancements in synthetic alternatives could pose risks. Kohjin Bio’s financial stability and niche focus provide resilience, but scaling beyond its core markets remains a challenge.